Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 28;8:14529. doi: 10.1038/s41598-018-32797-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of GLS-409 and vehicle control (saline) on coronary patency as measured by % flow-time area in a canine model of recurrent arterial thrombosis. % Flow-time area, quantified before and after treatment, in cohorts treated with saline (Control n = 3) and GLS-409 doses 1, 2 and 3. Dose 1: 0.054 mg/kg bolus + 0.00018 mg/kg/min infusion maintained for 2 hours (same bolus + 1/10 of the infused dose administered in the initial GLS-409 study, n = 3)¹². Dose 2: 0.0054 mg/kg bolus + 0.00018 mg/kg/min infusion for 2 hours (1/10 of the bolus + 1/10 of the infused dose administered in the initial study, n = 5). Dose 3: 0.00054 mg/kg bolus + 0.000018 mg/kg/min infusion for 2 hours (1/100 of the bolus + 1/100 of the infused dose administered in the initial study: n = 5). Insert: for purposes of comparison, data from the current study are plotted together with results obtained previously with high-dose GLS-409 (0.054 mg/kg IV bolus followed by a continuous intravenous infusion of 0.0018 mg/kg/min) and matched (historical) controls¹². Data are mean ± SEM, *p < 0.05 versus pretreatment and p < 0.05 versus controls.